Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) will release first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. Management will host a live webcast at 4:30 p.m. ET the same day with a brief Q&A following commentary.

Investors can access the live webcast at the provided events link or via the company's Investor Relations webcast page; a replay will be available after the presentation.

News Market Reaction – CSTL

+1.03%

+1.03% News Effect

On the day this news was published, CSTL gained 1.03%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Castle Biosciences’ Q1 2026 results and webcast on May 6, 2026...

Analysis

This announcement sets the timing for Castle Biosciences’ Q1 2026 results and webcast on May 6, 2026. Context includes previously disclosed 2025 revenue of $344 million and about $300 million in cash, along with strong test volume growth of 37%. Investors may focus on how Q1 performance compares to these benchmarks, as well as any updated commentary on clinical adoption trends, reimbursement dynamics, and capital allocation priorities discussed during the call.

Key Figures

2025 Revenue: $344 million Test volume growth: 37% Cash & securities: $300 million +5 more

8 metrics

2025 Revenue $344 million 2025 full-year revenue cited in DEF 14A

Test volume growth 37% DecisionDx-Melanoma and TissueCypher volumes vs 2024

Cash & securities $300 million Cash, cash equivalents and marketable securities reported in DEF 14A

Current price $24.37 Latest pre-news trading price for CSTL

Daily change 3.57% Price change in prior 24 hours before this earnings-date news

Market cap $700,745,670 Equity market capitalization before earnings-date announcement

Today’s volume 189,771 shares Trading volume vs 20-day average of 302,815 shares

Short interest 5.27% Short interest as a percentage of float

Historical Context

5 past events · Latest: Apr 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 10	Workplace award	Positive	-1.3%	Recognition as a 2026 USA TODAY Top Workplaces USA Award recipient.
Mar 27	Clinical data update	Positive	-4.7%	SEER-linked data showing DecisionDx-Melanoma improves five-year survival stratification.
Mar 13	Clinical study publication	Positive	+0.9%	Future Oncology study shows i31-SLNB outperforms staging in identifying low-risk patients.
Mar 09	Study results update	Positive	-0.4%	Prospective multicenter results confirm low nodal positivity and high three-year RFS.
Mar 04	Conference presentation	Positive	-0.9%	Upcoming SSO 2026 presentation on i31-SLNB identifying patients who may avoid SLNB.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive scientific and recognition news has often seen muted or negative next-day price reactions.

Recent Company History

Over the past six weeks, Castle Biosciences has highlighted multiple positive operational and clinical milestones. On Mar 4–13, 2026, several updates on DecisionDx-Melanoma’s i31-SLNB algorithm and prospective studies emphasized low SLN positivity and strong three-year RFS, yet price reactions ranged from -0.92% to +0.95%. On Mar 27, 2026, strong SEER-linked risk-stratification data preceded a -4.74% move. A workplace award on Apr 10, 2026 coincided with a -1.28% reaction. Against this backdrop, today’s announcement simply schedules the Q1 2026 earnings release and webcast.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRIENDSWOOD, Texas, April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the close of market on Wednesday, May 6, 2026.

Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Webcast Details
The live webcast can be accessed here: https://events.q4inc.com/attendee/621816679, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the start time. A replay of the webcast will be available following its conclusion.

There will be a brief Question and Answer session following management commentary.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/castle-biosciences-to-release-first-quarter-2026-financial-results-and-host-webcast-on-wednesday-may-6-2026-302741021.html

SOURCE Castle Biosciences, Inc.

FAQ

When will Castle Biosciences (CSTL) release Q1 2026 results and hold the earnings webcast?

Castle Biosciences will release Q1 2026 results after market close on Wednesday, May 6, 2026. According to the company, management will host a live webcast at 4:30 p.m. ET that same day with a short Q&A following prepared remarks.

How can investors access the Castle Biosciences (CSTL) May 6, 2026 webcast?

Investors can access the live webcast via the provided events link or the company's Investor Relations webcast page. According to the company, attendees should join at least 10 minutes before the 4:30 p.m. ET start time and a replay will be posted afterward.

Will Castle Biosciences (CSTL) provide a replay of the May 6, 2026 webcast?

Yes. A replay of the webcast will be available following the conclusion of the live presentation. According to the company, the replay can be accessed via the same webcast links on the events page or the Investor Relations site.

What time should I join the Castle Biosciences (CSTL) Q1 2026 webcast on May 6, 2026?

Attendees are advised to join at least 10 minutes before the 4:30 p.m. ET webcast start time. According to the company, early access helps resolve any technical issues and ensures participation in the brief Q&A after management remarks.

Will there be a Q&A during the Castle Biosciences (CSTL) May 6, 2026 webcast?

Yes. A brief Question and Answer session will follow management commentary during the webcast. According to the company, the Q&A is scheduled immediately after prepared remarks at the conclusion of the live presentation on May 6, 2026.